CABG Medical goes into liquidation after Holly Graft setbacks:
This article was originally published in Clinica
Executive Summary
CABG Medical has ceased trading after shareholders overwhelmingly approved plans to liquidate and dissolve the company. An initial distribution of $1.47 per share will be made this month and a second distribution, which could range up to $0.04 per share, will take place after the firm completes the shutdown of its Minneapolis, Minnesota-based operations. The company's stock had been offered at an initial price of $5.50 per unit, when it made its debut on the stock market at the end of 2004. The decision to close down came in February after the firm's clinical trials of its Holly Graft synthetic heart bypass graft suffered from a string of setbacks.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.